期刊
BRITISH JOURNAL OF CANCER
卷 94, 期 4, 页码 481-485出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6602966
关键词
advanced and metastatic pancreatic cancer; gemcitabine plus oxaliplatin; second line chemotherapy
类别
Gemcitabine and oxaliplatin (GEMOX) are active as first-line therapy against advanced pancreatic cancer. This study aims to evaluate the activity and tolerability of this combination in patients refractory to standard gemcitabine (GEM). A total of 33 patients (median age of 57) were included with locally advanced and metastatic evaluable diseases, who had progressed during or following GEM therapy. The GEMOX regimen consisted of 1000 mgm(-2) of GEM at a 100-min infusion on day 1, followed on day 2 by 100 mgm(-2) of oxaliplatin at a 2-h infusion; a cycle that was given every 2 weeks. All patients received at least one cycle of GEMOX (median 5; range 1-29). Response by 31 evaluable patients was as follows: PR: 7/31( 22.6%), s.d. >= 8 weeks: 11/31( 35.5%), s.d. < 8 weeks: 1/31( 3.2%), PD: 12/31( 38.7%). Median duration of response and TTP were 4.5 and 4.2 months, respectively. Median survival was 6 months (range 0.5-21). Clinical benefit response was observed in 17/31 patients (54.8%). Grade III/ IV non-neurologic toxicities occurred in 12/33 patients (36.3%), and grade I, II, and III neuropathy in 17(51%), 3(9%), and 4(12%) patients, respectively. GEMOX is a well-tolerated, active regimen that may provide a benefit to patients with advanced pancreatic cancer after progression following standard gemcitabine treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据